Fuan Pharmaceutical (300194.SZ) subsidiary has received approval for a chemical raw material drug to be listed.

16:05 26/02/2026

Fuan Pharmaceuticals (300194.SZ) announcement, the company's wholly-owned subsidiary Fuan Pharmaceuticals Group Ningbo Tianheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Tianheng Pharmaceutical") recently received the approval notice for the marketing application of the chemical raw material drug issued by the National Medical Products Administration. The raw material drug is called Metronidazole. Metronidazole is mainly used to treat infectious diseases caused by anaerobic bacteria (such as lower respiratory tract infections, pelvic inflammatory disease, sepsis, etc.).

Fuan Pharmaceutical (300194.SZ) announced that its wholly-owned subsidiary, Fuan Pharmaceutical Group Ningbo Tianheng Pharmaceutical Co., Ltd. (referred to as "Tianheng Pharmaceutical") recently received a notice of approval for the listing application of the chemical raw material drug, Metronidazole, issued by the National Medical Products Administration. Metronidazole is mainly used to treat infectious diseases caused by anaerobic bacteria (such as lower respiratory tract infections, pelvic inflammatory disease, sepsis, etc.).

HKEX (00388) will pay a second interim dividend of HK$6.52 per share on March 25th.

Goldwind Science & Technology (02208) repurchases and cancels 1.279 million shares of A restricted stocks.

On February 25th, STANCHART (02888) spent 8.8549 million pounds to repurchase 492,000 shares.

HKEX (00388) will pay a second interim dividend of HK$6.52 per share on March 25th.

Goldwind Science & Technology (02208) repurchases and cancels 1.279 million shares of A restricted stocks.

On February 25th, STANCHART (02888) spent 8.8549 million pounds to repurchase 492,000 shares.